WT1 expression as a marker of minimal residual disease predicts outcome in acute myeloid leukemia when measured post-consolidation

Leukemia Research

Volumn 36, Issue 4, 2012, Pages 453-458

  Gray, James X ^a   McMillen, Lyle ^b   Mollee, Peter ^b   Paul, Sanjoy ^c   Lane, Steven ^b   Bird, Robert ^b   Gill, Devinder ^b   Saal, Russell ^b   Marlton, Paula ^b,c  

^a QUEEN ELIZABETH HOSPITAL   (Australia)

^b PRINCESS ALEXANDRA HOSPITAL   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Acute myeloid leukemia; AML; Minimal residual disease; MRD; WT1

Indexed keywords

ARSENIC TRIOXIDE; CYTARABINE; IDARUBICIN; RETINOIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BLOOD; BONE MARROW; COHORT ANALYSIS; CONSOLIDATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOGENETIC RISK; FEMALE; GENE EXPRESSION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC PARAMETERS; HUMAN; HUMAN TISSUE; LEUKEMIA FREE SURVIVAL; LEUKEMIA RELAPSE; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROMYELOCYTIC LEUKEMIA; REPRODUCIBILITY; RETROSPECTIVE STUDY; SURVIVAL; TUMOR GENE; WILMS TUMOR 1 GENE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CONSOLIDATION CHEMOTHERAPY; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; NEOPLASM, RESIDUAL; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REAL-TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL; WT1 PROTEINS; YOUNG ADULT;

EID: 84857237509     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2011.09.005     Document Type: Article

References (27)

1. Freeman S.D., Jovanovic J.V., Grimwade D. Development of minimal residual disease-directed therapy in acute myeloid leukemia. Semin Oncol 2008, 35:388-400.
2. Doubek M., Palasek I., Pospisil Z., Borsky M., Klabusay M., Brychtova Y., et al. Detection and treatment of molecular relapse in acute myeloid leukemia with RUNX1 (AML1), CBFB, or MLL gene translocations: frequent quantitative monitoring of molecular markers in different compartments and correlation with WT1 gene expression. Exp Hematol 2009, 37:659-672.
3. Gabert J., Beillard E., van der Velden V.H., Bi W., Grimwade D., Pallisgaard N., et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. Leukemia 2003, 17:2318-2357.
4. Gaidzik V., Dohner K. Prognostic implications of gene mutations in acute myeloid leukemia with normal cytogenetics. Semin Oncol 2008, 35:346-355.
5. Barragan E., Pajuelo J.C., Ballester S., Fuster O., Cervera J., Moscardo F., et al. Minimal residual disease detection in acute myeloid leukemia by mutant nucleophosmin (NPM1): comparison with WT1 gene expression. Clin Chim Acta 2008, 395:120-123.
6. Gaidzik V.I., Schlenk R.F., Moschny S., Becker A., Bullinger L., Corbacioglu A., et al. Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia: a study of the German-Austrian AML Study Group. Blood 2009, 113:4505-4511.
7. Markova J., Trnkova Z., Michkova P., Maaloufova J., Stary J., Cetkovsky P., et al. Monitoring of minimal residual disease in patients with core binding factor acute myeloid leukemia and the impact of C-KIT, FLT3, and JAK2 mutations on clinical outcome. Leukemia Lymphoma 2009, 50:1448-1460.
8. Stirewalt D.L., Meshinchi S., Kopecky K.J., Fan W., Pogosova-Agadjanyan E.L., Engel J.H., et al. Identification of genes with abnormal expression changes in acute myeloid leukemia. Gene Chromosome Canc 2008, 47:8-20.
9. Yang L., Han Y., Suarez Saiz F., Minden M.D. A tumor suppressor and oncogene: the WT1 story. Leukemia 2007, 21:868-876. [erratum appears in Leukemia 2007;21:1603].
10. Sugiyama H. Wilms' tumor gene WT1: its oncogenic function and clinical application. Int J Hematol 2001, 73:177-187.
11. Cilloni D., Gottardi E., De Micheli D., Serra A., Volpe G., Messa F., et al. Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients. Leukemia 2002, 16:2115-2121.
12. Cilloni D., Messa F., Arruga F., Defilippi I., Gottardi E., Fava M., et al. Early prediction of treatment outcome in acute myeloid leukemia by measurement of WT1 transcript levels in peripheral blood samples collected after chemotherapy. Haematologica 2008, 93:921-924.
13. Cilloni D., Renneville A., Hermitte F., Hills R.K., Daly S., Jovanovic J.V., et al. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: A European LeukemiaNet Study. J Clin Oncol 2009, 27:5195-5201.
14. Hamalainen M.M., Kairisto V., Juvonen V., Johansson J., Auren J., Kohonen K., et al. Wilms tumour gene 1 overexpression in bone marrow as a marker for minimal residual disease in acute myeloid leukaemia. Eur J Haematol 2008, 80:201-207.
15. Lapillonne H., Renneville A., Auvrignon A., Flamant C., Blaise A., Perot C., et al. High WT1 expression after induction therapy predicts high risk of relapse and death in pediatric acute myeloid leukemia. J Clin Oncol 2006, 24:1507-1515.
16. Ommen H.B., Nyvold C.G., Braendstrup K., Andersen B.L., Ommen I.B., Hasle H., et al. Relapse prediction in acute myeloid leukaemia patients in complete remission using WT1 as a molecular marker: development of a mathematical model to predict time from molecular to clinical relapse and define optimal sampling intervals. Br J Haematol 2008, 141:782-791.
17. Ostergaard M., Olesen L.H., Hasle H., Kjeldsen E., Hokland P. WT1 gene expression: an excellent tool for monitoring minimal residual disease in 70% of acute myeloid leukaemia patients - results from a single-centre study. Br J Haematol 2004, 125:590-600.
18. Qin Y., Zhu H., Jiang B., Li J., Lu X., Li L., et al. Expression patterns of WT1 and PRAME in acute myeloid leukemia patients and their usefulness for monitoring minimal residual disease. Leuk Res 2009, 33:384-390.
19. Weisser M., Kern W., Rauhut S., Schoch C., Hiddemann W., Haferlach T., et al. Prognostic impact of RT-PCR-based quantification of WT1 gene expression during MRD monitoring of acute myeloid leukemia. Leukemia 2005, 19:1416-1423.
20. Paschka P., Marcucci G., Ruppert A.S., Whitman S.P., Mrozek K., Maharry K., et al. Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. J Clin Oncol 2008, 26:4595-4602.
21. Virappane P., Gale R., Hills R., Kakkas I., Summers K., Stevens J., et al. Mutation of the Wilms' tumor 1 gene is a poor prognostic factor associated with chemotherapy resistance in normal karyotype acute myeloid leukemia: the United Kingdom Medical Research Council Adult Leukaemia Working Party. J Clin Oncol 2008, 26:5429-5435.
22. Lasa A., Carricondo M., Estivill C., Bussaglia E., Gich I., Brunet S., et al. WT1 monitoring in core binding factor AML: comparison with specific chimeric products. Leuk Res 2009, 33:1643-1649.
23. Miyawaki S., Hatsumi N., Tamaki T., Naoe T., Ozawa K., Kitamura K., et al. Prognostic potential of detection of WT1 mRNA level in peripheral blood in adult acute myeloid leukemia. Leukemia Lymphoma 2010, 51:1855-1861.
24. Slovak M.L., Kopecky K.J., Cassileth P.A., Harrington D.H., Theil K.S., Mohamed A., et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000, 96:4075-4083.
25. Beillard E., Pallisgaard N., van der Velden V.H., Bi W., Dee R., van der Schoot E., et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program. Leukemia 2003, 17:2474-2486.
26. Hughes T., Branford S. Molecular monitoring of BCR-ABL as a guide to clinical management in chronic myeloid leukaemia. Blood Rev 2006, 20:29-41.
27. Hughes T., Deininger M., Hochhaus A., Branford S., Radich J., Kaeda J., et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006, 108:28-37.